PF 02341066 hydrochloride
- Product Name
- PF 02341066 hydrochloride
- CAS No.
- 1415560-69-8
- Chemical Name
- PF 02341066 hydrochloride
- Synonyms
- Crizotinib HCl;PF-2341066 hydrochloride);PF-02341066 hydrochloride;PF 02341066 hydrochloride;Crizotinib (hydrochloride);Crizotinib HCl,PF-02341066 HCl;Crizotinib hydrochloride, 10 mM in DMSO;PF-02341066 HYDROCHLORIDE;PF-2341066 HYDROCHLORIDE;Crizotinib hydrochloride (PF-02341066 hydrochloride;3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine:hydrochloride
- CBNumber
- CB12667482
- Molecular Formula
- C21H23Cl3FN5O
- Formula Weight
- 486.7976232
- MOL File
- 1415560-69-8.mol
PF 02341066 hydrochloride Property
- storage temp.
- Store at -20°C
- form
- Powder
- color
- Yellow to brown
- Water Solubility
- ≥ 100.4 mg/mL in DMSO, ≥ 101.4 mg/mL in EtOH, ≥ 52.2 mg/mL in Water
N-Bromosuccinimide Price
- Product number
- CS-1156
- Product name
- Crizotinib(hydrochloride)
- Purity
- 99.86%
- Packaging
- 10mg
- Price
- $60
- Updated
- 2021/12/16
- Product number
- B3608
- Product name
- Crizotinibhydrochloride
- Packaging
- 5mg
- Price
- $70
- Updated
- 2021/12/16
- Product number
- B3608
- Product name
- Crizotinibhydrochloride
- Packaging
- 10mg
- Price
- $110
- Updated
- 2021/12/16
- Product number
- CS-1156
- Product name
- Crizotinib(hydrochloride)
- Purity
- 99.86%
- Packaging
- 50mg
- Price
- $120
- Updated
- 2021/12/16
- Product number
- CS-1156
- Product name
- Crizotinib(hydrochloride)
- Purity
- 99.86%
- Packaging
- 100mg
- Price
- $168
- Updated
- 2021/12/16
PF 02341066 hydrochloride Chemical Properties,Usage,Production
Uses
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].
in vivo
PF-2341066 reveals the ability to cause marked regression of large established tumors (> 600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule in the GTL-16 model. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. A significant dose-dependent reduction of CD31-positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066[1].
Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1[4].
References
[1] Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67(9), 4408-4417. DOI:10.1158/0008-5472.CAN-06-4443
[2] Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322. DOI:10.1158/1535-7163.MCT-07-0365
[3] Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. DOI:10.1021/jm2007613
[4] Cullinane C, et al. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52(8):1261-7 DOI:10.2967/jnumed.110.086967
PF 02341066 hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
PF 02341066 hydrochloride Suppliers
- Tel
- 0531-88811783
- Fax
- +86 (531) 55696010 QQ 1762738062
- sales@trio-pharmatech.com
- Country
- China
- ProdList
- 1856
- Advantage
- 62
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Country
- China
- ProdList
- 4765
- Advantage
- 58
- Tel
- 021-58950125
- Fax
- (86) 21-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 7552
- Advantage
- 61
- Tel
- 021-61552785
- Fax
- 021-55660885
- sales@shshiji.com
- Country
- China
- ProdList
- 9546
- Advantage
- 55
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- 020-39119399 18927568969
- Fax
- 020-39119999
- isunpharm@qq.com
- Country
- China
- ProdList
- 4720
- Advantage
- 55
- Tel
- 18149758185 18149758185;
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3505
- Advantage
- 58
- Tel
- 400-0066400 13621662912
- Fax
- 021-55660885
- 422131432@qq.com
- Country
- China
- ProdList
- 9979
- Advantage
- 55
- Tel
- 028-81700200 18116577057
- Fax
- 028-81705658
- 3003855609@qq.com
- Country
- China
- ProdList
- 7778
- Advantage
- 56
- Tel
- +86-21-5821 5861
- Fax
- +86-21-5106 2861
- sales@letopharm.com
- Country
- China
- ProdList
- 2384
- Advantage
- 58
View Lastest Price from PF 02341066 hydrochloride manufacturers
- Product
- PF 02341066 hydrochloride 1415560-69-8
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 1000KG
- Release date
- 2018-08-15